ClinicalTrials.Veeva

Find clinical trials for Non-Small-Cell Lung Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Non-Small-Cell Lung Cancer trials near Birmingham, AL, USA:

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non- ...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Zimberelimab
Drug: Domvanalimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Birmingham, Alabama, United States and 64 other locations

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung)

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Platinum-Based Doublet
Drug: Domvanalimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Birmingham, Alabama, United States and 23 other locations

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small ...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Cancer
Drug: Cofetuzumab Pelidotin

Phase 1

AbbVie
AbbVie

Birmingham, Alabama, United States and 25 other locations

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

Phase 2

NovoCure
NovoCure

Birmingham, Alabama, United States of America and 23 other locations

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC).The prim...

Active, not recruiting
NSCLC
Drug: REGN5093

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Birmingham, Alabama, United States and 29 other locations

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) wit...

Enrolling
Advanced Non-Small Cell Squamous Lung Cancer
Advanced Lung Carcinoma
Drug: BDTX-1535 monotherapy

Phase 1, Phase 2

Black Diamond Therapeutics

Birmingham, Alabama, United States and 25 other locations

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patient...

Active, not recruiting
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Other: Best Standard of Care
Device: NovoTTF-200M device

Phase 3

NovoCure
NovoCure

Birmingham, Alabama, United States and 127 other locations

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The ...

Active, not recruiting
Non-squamous, Non-Small-Cell Lung Cancer
Neoplasms
Drug: ezabenlimab
Drug: BI 836880

Phase 1

Boehringer Ingelheim
Boehringer Ingelheim

Birmingham, Alabama, United States and 42 other locations

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-S ...

Enrolling
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Cisplatin

Phase 3

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 223 other locations

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)

with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after...

Active, not recruiting
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Drug: Sitravatinib
Drug: Docetaxel

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Birmingham, Alabama, United States and 233 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems